Treating acute myelogenous leukemia in patients aged 70 and above: Recommendations from the International Society of Geriatric Oncology (SIOG).

Acute myeloid leukemia (AML) treatment is challenging in older patients. There is a lack of evidence-based recommendations for older patients ≥70, a group largely underrepresented in clinical trials. With new treatment options being available in recent years, recommendations are needed for these patients. As such the International Society of Geriatric Oncology (SIOG) assembled a task force to review the evidence specific to treatment and outcomes in this population of patients ≥70 years. Six questions were selected by the expert panel in domains of (1) baseline assessment, (2) frontline therapy, (3) post-remission therapy, (4) treatment for relapse, (5) targeted therapies, and (6) patient reported outcome/function and enhancing treatment tolerance. Information from current literature was extracted, combining evidence from systematic reviews/meta-analyses, decision models, individual trials targeting these patients, and subgroup data. Accordingly, recommendations were generated using a GRADE approach upon reviewing current evidence by consensus of the whole panel. It is our firm recommendation and hope that direct evidence should be generated for patients aged ≥70 as a distinct group in high need of improvement of their survival outcomes. Such studies should integrate information from a geriatric assessment to optimize external validity and outcomes.
Competing Interests: Declaration of Competing Interest Disclosures: Dr. Extermann: Aileron, Alnylam (consultant), OncLive (honoraria). Dr. Artz: Abbvie, Magenta (consulting). Dr. Klepin: UptoDate (contributor). DrLoh: COI: Dr. Loh: Pfizer and Seagen (consultant), Pfizer (honoraria). Dr. Neuendorff: Janssen-Cilag, Medac, Novartis, Abbvie, and Jazz Pharmaceutical (honoraria, travel support). Dr. Santini: Abbvie, CTI, Celegne/BMS, Geron, Gilead, Novartis, Otsuka, Serveir, Syros (advisory boards), AIRC Foundation, Associazione Italiana per la Ricerca contro il Cancro, Milan Italy – Project. IG # 26537 (grant). Dr. Stauder: Celgene/BMS (Advisory board); Celgene/BMS (Honoraria); Celgene/BMS (Research funding). Dr. Vey: Celgene/BMS, Novartis, Roche, Jazz Pharmaceuticals (honoraria).
(Copyright © 2023. Published by Elsevier Ltd.)